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Abstract
Copy number variants (CNVs) account for a major proportion of human genetic polymorphism
and have been predicted to play an important role in genetic susceptibility to common disease. To
address this we undertook a large direct genome-wide study of association between CNVs and
eight common human diseases. Using a purpose-designed array we typed ~19,000 individuals into
distinct copy-number classes at 3,432 polymorphic CNVs, including an estimated ~50% of all
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common CNVs larger than 500bp. We identified several biological artefacts that lead to false-
positive associations, including systematic CNV differences between DNAs derived from blood
and cell-lines. Association testing and follow-up replication analyses confirmed three loci where
CNVs were associated with disease, IRGM for Crohn's disease, HLA for Crohn's disease,
rheumatoid arthritis, and type 1 diabetes, and TSPAN8 for type 2 diabetes, though in each case the
locus had previously been identified in SNP-based studies, reflecting our observation that the
majority of common CNVs which are well-typed on our array are well tagged by SNPs and so
have been indirectly explored through SNP studies. We conclude that common CNVs which can
be typed on existing platforms are unlikely to contribute greatly to the genetic basis of common
human diseases.
Genome-wide association studies (GWAS) have been extremely successful in associating
single nucleotide polymorphisms (SNPs) with susceptibility to common diseases, but
published SNP associations account for only a fraction of the genetic component of most
common diseases, and there has been considerable speculation about where the “missing
heritability” 1 might lie. Chromosomal rearrangements can cause particular rare diseases and
syndromes 2, and recent reports have suggested a role for rare copy number variants, either
individually or in aggregate, in susceptibility for a range of common diseases, notably
neurodevelopmental diseases 3,4,5,6. To date, there have been relatively few reported
associations between common diseases and common CNVs, see for example 7,8,9,10,11,
which might simply reflect incomplete catalogues of common CNVs or the lack of reliable
assays for their large-scale typing. Here we report the results of our direct association study,
identify the population properties of the set of CNVs studied, describe novel analytical
methods to facilitate robust analyses of CNV data, and document artefacts that can afflict
CNV studies.
We designed an array to measure copy number for the majority of a recently-compiled
inventory of CNVs from an extensive discovery experiment 12, and several other sources.
We then used the array to type 3,000 common controls and 2,000 cases of each of the
diseases: bipolar disorder (BD), breast cancer (BC), coronary artery disease (CAD), Crohn's
disease (CD), hypertension (HT), rheumatoid arthritis (RA), type 1 diabetes (T1D), and type
2 diabetes (T2D). These eight diseases make a major impact on public ill health 13, cover a
range of aetiologies and genetic predispositions, and have been extensively studied via SNP-
based GWAS, including our earlier Wellcome Trust Case Control Consortium (WTCCC)
study 14.
Pilot experiment, Array Content, Assay, and Samples
Pilot experiment
We undertook a pilot experiment to compare three different platforms for assaying copy-
number variation and to assess the merits of different experimental design parameters (full
details are given in the SoM). Based on the pilot data, we chose the Agilent Comparative
Genomic Hybridisation (CGH) platform, and aimed to target each CNV with 10 distinct
probes, although in the analyses below we include any CNV targeted by at least one probe
(Supplementary Figure 9). Our analysis of the pilot CGH data indicated that the quality of
the copy number signal for genotyping (rather than for discovery) at a CNV is reduced when
the reference sample is homozygous deleted, in effect because the reference channel then
just measures noise. To minimize this effect we used a fixed pool of DNAs as the reference
sample throughout our main experiment.
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Array Content
Informed by our pilot experiment, we designed the CNV-typing array in a collaboration with
the Genome Structural Variation Consortium (GSV) in which a preliminary set of candidate
CNVs was shared at an early stage with the WTCCC. Table 1 summarises the design
content of the array, and Figure 1 illustrates the various categories of designed loci
unsuitable for association analysis. See online methods for further details.
Assay
In brief (see SoM for further details) the Agilent assay differentially labels parallel aliquots
of the test sample and reference DNA (a pool of genomic UK lymphoblastoid cell-line
DNAs from 9 males and 1 female prepared in a single batch for all experiments) and then
combines them, hybridises to the array, washes, and scans. Intensity measurements for the
two different labels are made at each probe separately for the test and reference DNA. These
act as surrogates for the amount of DNA present, with analyses typically relying on the ratio
of test to reference intensity measurements at each probe.
Samples
A total of 19,050 case-control samples were sent for assaying: ~2,000 for each of the eight
diseases and ~3000 common controls (these were equally split between the 1958 British
Birth Cohort (58C) and the UK Blood Services (UKBS) controls). These were augmented
by 270 HapMap1 samples (see 12 for additional analyses of the HapMap data) and 610
duplicate samples for QC purposes. About 80% of samples from the WTCCC SNP GWAS
were used here. See SoM for further details of sample collections, inclusion criteria etc.
Data Pre-Processing, CNV Calling and Quality Control
Data Pre-Processing
For each sample, raw data from the CNV experiment consist of intensity measurements for
the test and reference sample for each probe. There are numerous choices at the data pre-
processing stage, including how to normalise data to reduce inter-individual variation, and
how to combine the information across the set of probes within a CNV. Several novel
analytical tools substantially improved data quality, but no single approach works well for
every CNV, so we carried through 16 pre-processing pipelines to maximise the number of
CNVs that can be tested for association. See SoM Section 4 for illustrations and a sense of
the challenges.
CNV Calling
The objective in CNV calling at each CNV is to assign each assayed sample to a diploid
copy-number class, which represents the sum of copy numbers on each allele. This step is
analogous to, but typically considerably more challenging than, calling genotypes from
SNP-chip data. Available assays for SNPs are more robust and have better signal to noise
properties than do available assays for CNVs 15. We used two different statistical methods
(“CNVtools” which is available as a Bioconductor package, and “CNVCALL”) in parallel to
estimate the number of copy-number classes at each CNV and assign individuals to these
classes. See SoM for further details. Figure 2 illustrates three multi-allelic CNVs which have
attracted attention in the literature in part due to the difficulties in obtaining reliable data.
Quality Control
Following the application of QC metrics to each sample and each CNV (see Online
Methods) 17,304 case control samples (of 19,050 initially) were available for association
testing. There were 3,432 CNVs with more than one copy-number class which passed QC
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and were included in subsequent analyses. At these CNVs, concordance of calls between
pairs of duplicate samples was 99.7%.
Properties of CNVs
Single class CNVs
Of the 10,894 distinct putative CNVs typed on the array after removal of detectable
redundancies, 60% are called with a single copy-number class, and so cannot be tested for
association. Following detailed analyses (see Online Methods) we estimate that just under
half of these are likely not to be polymorphic. For the remainder, the combination of the
experimental assay and analytical methods we have used do not allow separate copy-number
classes to be distinguished.
Multi-class CNVs
4,326 CNVs were called with multiple classes. Of these, 3,432 passed quality control filters,
which in practice means that the classes were well separated and thus that it was possible to
assign individuals to copy-number classes with high confidence. Most of these CNVs (88%)
have two or three copy-number classes, consistent with their having only two variants, or
alleles, present in the population (we refer to these as bi-allelic CNVs). Note that some loci
involving both duplications and deletions could be called with only three classes if both
homozygote classes are very rare.
Allele Frequencies
Supplementary Figure 21 shows the distribution of minor allele frequency (MAF) for bi-
allelic CNVs passing QC. For example, 44% of autosomal CNVs passing QC had MAF <
5%. This is shifted towards lower MAFs compared to commonly used SNP chips. One
consequence is that for given sample sizes association studies will tend to have lower power
than for SNP studies. (See Supplementary Figure 22 for power estimates.) Extrapolating
from analyses described in 12 gives an estimate that the 3,432 CNVs we directly tested
represent 42-50% of common (MAF > 5%) CNVs greater than 0.5kb in length which are
polymorphic in a population with European ancestry.
Tagging by SNPs
In the literature discussing the possible role of common CNVs in human disease, there has
been controversy over the extent to which CNVs will be in linkage disequilibrium (LD) with
SNPs. If LD between CNVs and SNPs were similar to that between SNPs, SNPs typed in
GWAS would act as tags not only for untyped SNPs but also for untyped CNVs, and in turn
SNP-based GWAS studies would have indirectly explored copy-number variation for
association with disease. (See for example 16 and 17 for opposite views.) Our large-scale
genotyping of an extensive CNV catalogue allows us to settle this question. In fact, CNVs
that are typed well in our experiment are in general well-tagged by SNPs – almost to the
same extent that SNPs are well-tagged by SNPs (Supplementary Figure 20). Amongst
variable 2- and 3-class CNVs passing QC with MAF > 10%, 79% have r2 > 0.8 with at least
one SNP, for those with MAF < 5%, 22% have r2 > 0.8 with at least one SNP. This is
consistent with the vast majority having arisen from unique mutational events at some time
in the past. It follows that genetic variation, in the form of common CNVs which can be
typed on our array, has already been explored indirectly for association with common
human disease through the SNP-based GWAS. In passing, we note that the high correlations
between our CNV calls and SNP genotypes provides strong indirect evidence that our CNV
2The Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, CB10 1SA UK.
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calls are capturing real variation. It is possible that the CNVs which we cannot type well are
systematically different from those we can type, for example in having many more copy-
number classes, and hence perhaps that they arise from repeated mutational events in the
same region, in which case their LD properties with SNPs could also be systematically
different from the CNVs we can type. We have no data that bear on this question, and it
seems likely that such CNVs will be difficult to type genome-wide on any currently-
available platforms.
Association Testing
We performed association testing at each of the CNVs which passed QC, in two parallel
approaches. First, we applied a frequentist likelihood ratio association test that combines
calling (using CNVtools) and testing into a single procedure, using an extension of an
approach previously described 18. Second, we undertook Bayesian association analyses in
which the posterior probabilities from CNVCALL were used to calculate a Bayes Factor to
measure strength of association with the disease phenotypes. Important feature of both sets
of analyses are that they correctly handle uncertainty in assignment of individuals to copy-
number classes, and by allowing for some systematic differences in intensities between
cases and controls, that they provide robustness against certain artefacts which could arise
from differences in data properties between cases and controls. There were no substantial
differences between the broad conclusions from the frequentist and Bayesian approaches.
Our association analyses were based on a model in which a single parameter quantifies the
increase in disease risk between successive copy number classes, analogous to that
underlying the trend test for SNP data. Various analyses of the robustness of our procedure,
adequacy of the model, and lack of population structure were encouraging (see SoM and
Online Methods). For example, Supplementary Figure 23 shows quantile-quantile (QQ)-
plots for the primary comparison of each case collection against the combined controls, and
for the analogous comparisons between the two control groups. These show generally good
agreement with the expectation under the null hypothesis.
Careful analysis of our association testing revealed several sophisticated biological artefacts
which can lead to false positive associations. These include dispersed duplications, whereby
the variation at a CNV is not in the chromosomal location in the reference sequence to
which the probes in the CNV uniquely match, and a DNA source effect whereby particular
CNVs, and genome-wide intensity data, can look systematically different according to
whether the assayed DNA was derived from blood or cell-lines. See Box “Some Artefacts in
CNV Association Testing” for illustrations and further details.
Independent replication of putative association signals is a routine and essential aspect of
SNP-based association studies. Particularly in view of the differences in data quality
between SNP assays and CNV assays, and the wide range of possible artefacts in CNV
studies, replication is even more important in the CNV context. Several possible approaches
to replication are available. When a CNV is well-tagged by a SNP (or SNPs), replication can
be undertaken by assessment of the signal at the tag SNP(s) in an independent sample, either
by typing the SNP or by reference to published data. Where no SNP tag is available, direct
typing of the CNV in independent samples is necessary, either using a qualitative breakpoint
assay or a quantitative DNA dosage assay. In most cases there will be a choice of assays.
Interestingly, replication via SNPs was possible for 15 out of 18 of the CNVs for which we
undertook replication based on analysis of our penultimate data freeze.
Figure 3 plots p-values for the primary frequentist analysis for each CNV in each collection.
Table 2 provides details of the top, replicated, association signals in our experiment after
visual inspection of cluster plots to detect artefacts not removed by earlier QC. Cluster plots
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for each CNV in Table 2 are shown in Supplementary Figures 18 and 19, and
Supplementary Files 2 and 3.
There is one positive control for the diseases we studied, namely the known CNV
association at the IRGM locus in Crohn's disease 7. Reassuringly, our study found this
association (p= 1 × 10−7, odds ratio (OR) = 0.68; throughout, all ORs are with respect to
increasing copy number).
We identified three loci – HLA for Crohn's disease, rheumatoid arthritis, and type 1
diabetes; IRGM for Crohn's disease; and TSPAN8 for type 2 diabetes – at which CNVs
appeared associated with disease, all of which we convincingly replicated through
previously typed SNPs that tag the CNV, and a fourth locus (CNV7113.6), at which there is
suggestive evidence for association and replication in both Crohn's disease and type 1
diabetes.
We observed CNVs in the HLA region associated variously with Crohn's disease
(CNVR2841.20, p= 1.2 × 10−5, OR = 0.80), rheumatoid arthritis (CNVR2845.14, p= 1.4 ×
10−39, OR = 1.77), and type 1 diabetes (CNVR2845.46, p= 8 × 10−153, OR = 0.2). Copy
number variation has previously been documented on various HLA haplotypes 19 and due to
the extensive linkage disequilibrium in the region it is perhaps not unexpected to have found
CNV associations in our direct study. Linkage disequilibrium across the HLA region has
hampered attempts to fine-map causal variation across this locus, and we have no evidence
that suggests that the HLA CNVs associated with autoimmune diseases in this study
represent signals independent of the known associated haplotypes.
We identified two distinct CNVs 22kb apart upstream of the IRGM gene, both of which are
associated with Crohn's disease. The longer CNV (CNVR2647.1, p= 1.0 × 10−7, OR = 0.68)
has previously been identified 7 as a possible causal variant on an associated haplotype first
identified through SNP GWAS 14, and acted as our positive control but the association of
the smaller CNV (CNVR2646.1, p= 1.1 × 10−7, OR = 0.68, located <2kb downstream from
a different gene, MST150) is a novel observation. While direct experimental evidence links
the associated haplotypes with variation in expression of the IRGM gene, it does not bear on
the question of which of the two CNVs or the associated SNPs might be driving this
variation 7. Our conditional regression analyses on the two CNVs and SNPs on this
haplotype do not point significantly to any one of these as being more strongly associated.
SNP variation in the TSPAN8 locus was recently shown to be reproducibly associated with
type 2 diabetes 20, but the potential role of a CNV is a novel observation. This CNV
(CNVR5583.1, p= 3.9 × 10−5, OR = 0.85) potentially encompasses part or all of an exon of
TSPAN8 and so is a plausible causal variant. The most significantly associated SNP
identified in the recent meta-analysis is only weakly correlated with the CNV as originally
tested (r2 =0.17), and so the CNV may simply be weakly correlated with the true causal
variant. Closer examination of probe-level data at this CNV suggests a series of different
events (including an inverted duplication and a deletion) resulting in more complex
haplotypes than those tested for association by our automated approach. With this more
refined definition of haplotypes the signal is somewhat stronger. See SoM for details.
CNVR7113.6 lies within a cluster of segmentally duplicated sequences that demarcate one
end of a common 900kb inversion polymorphism on chromosome 17 that has previously
been shown to be associated with number of children and higher meiotic recombination in
females 21. The CNV shows weak evidence for association with Crohn's disease (p= 1.8 ×
10−3, OR = 1.15) and type 1 diabetes (p= 1.1 × 10−3, OR = 1.13), but is in extremely high
LD (r2=1) with SNPs known to tag the inversion, and so is in tight LD with a long haplotype
spanning many possible causal variants. This CNV encompasses at least one spliced
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transcript, but no high confidence gene annotations. Fine-mapping the causal variant within
such a long, tightly-linked, haplotype is likely to prove challenging.
In addition to the loci in Table 2, we undertook replication on thirteen other loci, detailed in
Supplementary Table 13, for which there was some evidence of association (p<1×10−4 or
log10(Bayes Factor [BF])> 2.1) in our analysis of the penultimate data freeze. Replication
results were negative for all these loci. Several other loci for which there is weak evidence
(p < 1×10−4 or log10(BF) > 2.6) for association in our final data analysis are listed in
Supplementary Table 14.
To further investigate the potential role of CNVs as pathogenically relevant variants
underlying published SNP-associations we took 94 association intervals in T1D, CD, and
T2D (excluding the HLA), and for the index SNP in each association interval assessed its
correlation with our calls at 3,432 CNVs. We identified two index SNPs as being correlated
with an r2 of greater than 0.5 with a called CNV. The SNPs were: rs11747270 with both
CNVR2647.1 and CNVR2646.1 (IRGM), and rs2301436 and CNVR3164.1 (CCR6), both
for Crohn's disease. Both of these association intervals were also identified in an
independent analysis using CNV calls on HapMap samples by Conrad et al. 12.
As a further test of our approach, we examined three multi-allelic CNVs which have
attracted attention in the literature, both for the challenges of obtaining reliable data, and for
putative associations with a range of autoimmune diseases: CCL3L1 (our CNVR7077.12);
Beta-Defensins (CNVR3771.10), and FCGR3A/B (CNVR383.1) 10,22,23,24. Encouragingly,
all three CNVs pass QC and give good data. Figure 2 shows cluster plots for these CNVs in
our experiment. The best calls for the three CNVs required the use of two analysis pipelines
(sets of choices about normalisation and probe summaries) different from our standard
pipeline. None of the CNVs shows significant association with the three autoimmune
diseases in our study after allowance for multiple testing. In particular, we do not see
formally significant evidence to replicate the reported association for CCL3L1 and
rheumatoid arthritis 24 (nominal p = 0.058).
We also assessed whether CNVs which delete all or part of exons might be enriched
amongst disease susceptibility loci, even if our study were not well-powered enough to see
statistically significant evidence of association for individual CNVs. To do so, we compared
the 53 exonic deletion CNVs 12 which passed QC with collections of CNVs of the same
size, matched for MAF and numbers of classes. We used a (two-sided) Wilcoxon signed-
rank test 25 to ask whether the strength of signal for association (measured by Bayes
Factors) was systematically different for the exon-deletion CNVs as compared to the
matched CNVs. We found no evidence that deletion of an exon systematically changed
evidence for association (see SoM). In a related analysis, we compared CNVs passing QC
which were well tagged by SNPs (r2 > 0.8) to those passing QC which were not, again
matching for MAF and number of classes (excluding low MAF CNVs and those failing
Hardy-Weinberg equilibrium tests to avoid calling artefacts). There was no evidence that
CNVs passing QC which are not well tagged by SNPs are enriched for stronger signals of
association compared to those which were well tagged (see SoM).
Discussion
We have undertaken a genome-wide association study of common copy-number variation in
eight diseases, by developing a novel array targeting most of a recently discovered set of
CNVs. Our findings inform understanding of the genetic contributions to common disease,
offer methodological insights into CNV analysis, and provide a resource for human genetics
research.
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One major conclusion is that considerable care is needed in analysing copy-number data
from array CGH experiments. Choices of normalisation, probe summary, and probe
weighting can make major differences to data quality and utility in association testing.
Strikingly, the optimal choices vary greatly across the CNVs we studied.
A second major conclusion is that CNV association analyses are susceptible to a range of
artefacts which can lead to false positive associations. Some are a consequence of the less-
robust nature of the data compared to SNP-chips. But others, such as systematic differences
depending on DNA source (eg. blood v. cell lines), and dispersed duplications, are more
subtle. Several artefacts could survive replication studies. Simultaneously studying eight
diseases helped greatly in identifying these artefacts and stringent QC was invaluable in
eliminating false positive associations. At least for currently available CNV-typing
platforms, we recommend considerable care in interpreting putative CNV associations
combined with independent replication, on a different experimental platform.
Despite the important technical challenges and potential artefacts discussed above, we have
demonstrated that high-confidence CNV calls can be assigned in large, real-world case-
control samples for a substantial proportion of the common copy number variation estimated
to be present in the human genome. We have identified directly several CNV loci that are
associated with common disease. Such loci could contribute to disease pathogenesis.
However, the loci identified are well tagged by SNPs and, hence, the associations can be,
and were, detected indirectly via SNP association studies.
There is a striking difference between the number of confirmed, replicated associations from
our CNV study (3 loci) and that from the comparably-powered WTCCC1 SNP-GWAS of
seven diseases and its immediate follow-up (~24 loci). (In assessing the importance of
CNVs in disease, it is the absolute number of associations, rather than the proportion among
loci tested, which is important.) Following 12 we estimated that our study directly tests
approximately half of all autosomal CNVs >500bp long, with MAF >5%. For such CNVs,
our power averages over 80% for effects with odds ratios >1.4, and ~50% for odds ratio
=1.25 (Supplementary Figure 22). We conclude that at least for the eight diseases studied,
and probably more generally, there are unlikely to be many associated CNVs with effects of
this magnitude.
Might there be many more common disease-associated CNVs each of small effect, in the
way we now know to be the case with SNP associations for many diseases? The total
number of CNVs over 500bp with MAF > 5% is limited (estimated to be under 4,000 12), so
unless many of these simultaneously affect many different diseases (something for which we
saw no evidence outside HLA) there would seem to be insufficient such CNVs for hundreds
to be associated with each of many common diseases. In addition, most common CNVs
(MAF > 5%) are well tagged by SNPs, and thus amenable to indirect study by SNP GWAS.
Examining the large meta-analyses of SNP GWAS for Crohn's disease, type 1 and type 2
diabetes, there were 95 published associated loci of which only 3, including HLA, had the
property that CNVs correlated with the associated SNPs; two of these were detected in our
direct study.
We conclude that common copy number variants typable on current platforms are unlikely
to play a major role in the genetic basis of common diseases, either through particular CNVs
having moderate or large effects (odds ratios > 1.3 say) or through many such CNVs having
small effects. In particular, such common CNVs seem unlikely to account for a substantial
proportion of the “missing heritability” for these diseases. Amongst the CNVs we could type
well, those not well-tagged by SNPs have the same overall association properties as those
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which are well-tagged. We saw no enrichment of association signals amongst CNVs
involving exonic deletions.
We have argued elsewhere 14 that the concept of “genome-wide significance” is misguided,
and that under frequentist and Bayesian approaches it is not the number of tests performed,
but rather the prior probability of association at each locus, which should determine
appropriate p-value thresholds. Here, to reduce the possibility of missing genuine
associations, we deliberately set relaxed thresholds for taking CNVs into replication studies.
Having completed these analyses the hypothesis that, a priori, an arbitrary common CNV is
much more likely than an arbitrary common SNP to affect disease susceptibility is not
supported by our data.
Limitations
Our findings should be interpreted within the context of several limitations. First, despite our
successes in robustly testing some of the previously noted challenging CNVs in the genome,
for some CNVs we could not reliably assign copy number classes from our assay. We
estimate that somewhat under half of these were not polymorphic in our data, being either
false positives in the discovery experiment, or very rare in the UK population. For the
remainder, we were also unable to perform reliable association analyses based directly on
intensity measurements (that is, without first assigning individuals to copy number classes;
data not shown). Such CNVs might plausibly be systematically different from those we do
type successfully, in which case it is not possible to extrapolate from our results to their
potential role in human disease. Second, we note that we have not studied CNVs of
sequences not present in the reference assembly, high-copy number repeats such as LINE
elements, or most polymorphic tandem repeat arrays and our findings may not generalize to
such variation. Finally, our experiment was powered to detect associations with common
copy number variation and our observations and conclusions do not necessarily generalize to
the study of rare copy number variants. Different approaches will be necessary to investigate
the contribution of such variation to common disease.
Methods Summary
A detailed description of materials and methods is given in Online Methods with further
details in SoM.
Pilot Study
A total of 384 samples spanning a range of DNA quality were assayed for 156 previously-
identified CNVs on each of three different platforms: Agilent CGH, NimbleGen CGH and
Illumina iSelect. The pilot experiment contained many more probes per CNV than we
anticipated using in the main study, and replicates of these probes, to allow an assessment of
data quality as a function of the number of probes per CNV and of the merits of replicating
probes predicted in advance to perform well, compared to using distinct probes.
Sample Selection
Case samples came from previously established UK collections. Control samples came from
two sources: half from the 1958 Birth Cohort and half from a UK Blood Service sample.
Approximately 80% of samples had been included within the WTCCC SNP GWAS study.
The 610 duplicate samples were drawn from all collections.
Array Design
The main study used an Agilent CGH array comprising 105,072 long oligonucleotide
probes. Probes were selected to target CNVs identified mainly through the GSV discovery
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experiment 12 with some coming from other sources. Ten non-polymorphic regions of the
X-chromosome were assayed for control purposes.
Array Processing
Arrays were run at Oxford Gene Technology (OGT). The samples were processed in batches
of 47 samples drawn from two different collections, with each batch containing one control
sample for QC purposes. These batches were randomised to protect against systematic
biases in data characteristics between collections.
Data Analysis
Primary data and low-level summary statistics were produced at OGT. All substantive data
analyses were undertaken within the consortium. Plates failing QC metrics were rerun as
were 1,709 of the least well-performing samples. Details of the common CNVs assayed in
this study, including any tag SNP, are given in supplementary data (http://
www.wtccc.org.uk/wtcccplus_cnv/supplemental.shtml).
Box
Some Artefacts in CNV Association Testing
Some types of artefacts, such as population structure and calling artefacts, are very
similar to those seen in SNP studies. Others, related to differences in data properties
between cases and controls, can be potentially more serious for CNVs 26,27. In this box
we draw attention to some specific artefacts of biological interest that we observed and
which researchers should consider as explanations of putative disease-relevant
associations. We note that, for the unwary, some of these artefacts could easily survive
“replication” of an association.
Dispersed CNVs
Box Figure 1 shows cluster plots for a particular CNV (CNVR2664.1) which exhibits a
strong case-control association signal for breast cancer cases (p = 5×10−143, higher copy
number for disease) with a similar signal for rheumatoid arthritis (p = 3×10−27), and a
signal in the opposite direction for coronary artery disease (p=4×10−30). The right hand
class (green curve) has a higher frequency in BC (and RA), and a lower frequency in
CAD. (Area under green curve is the same for each collection.) This turned out to be an
artefact caused by differences in sex ratio in the various case and control samples (breast
cancer: 100% female; rheumatoid arthritis: 74% female; coronary artery disease: 22%
female; controls: 50% female). Comparing breast cancer cases against female controls
abolished the signal. The CNV is annotated as being on chromosome 5 and all 10 probes
in the CNV map uniquely to chromosome 5 in the human reference sequence. However,
we found that SNPs which tagged the variation at this CNV all mapped to the X-
chromosome and that the region containing the probes for this CNV is present on the X-
chromosome in the Venter genome. We conclude that the CNV is a dispersed
duplication, with the variation actually occurring on the X-chromosome, and not on
chromosome 5. We found one similar example, of a CNV (CNVR1065.1, featuring in
Table 2 as a replicated association) annotated as mapping uniquely to chromosome 2
which shows a strong signal in type 1 diabetes and rheumatoid arthritis. Careful
examination shows it to be another dispersed duplication where the polymorphism is
located in the HLA, and is well tagged by HLA SNPs known to be associated with both
diseases. Supplementary Figure 27 shows the clear evidence from inter-chromosomal
linkage disequilibrium that these two loci are dispersed duplications.
Variation in DNA source
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Box Figure 2 shows cluster plots for a different CNV (CNVR866.8) with striking
differences in T2D as compared with the UKBS controls (or against just the 58C
controls). The plots show histograms of normalised intensity ratios for 6 collections.
Examination of the pattern across collections is interesting. The collections in the top row
show a single tight peak towards the right of the plot. Those in the bottom row show a
single, more dispersed, peak to the left. The collections in the middle row show evidence
of both peaks. It turns out that for collections with the tight peak all DNA samples were
derived from blood whereas all samples in the two collections with the single dispersed
peak had DNA derived from cell lines. The remaining collections contain some DNAs
derived from both sources. This CNV (and many others) thus exhibit systematically
different behaviour depending on the DNA source. Box Figure 3 shows a plot of the
second (PC2) and third (PC3) principal components of the array-wide intensity data (plot
created using all samples post QC from all 10 collections using data from all CNVs with
each point representing one sample, with the points coloured according to whether that
sample was derived from blood (red) or cell-lines (blue)). It is clear that these two
components can almost perfectly classify samples according to the source of the DNA.
Lymphoblastoid cell lines are typically grown from transformed B-cells, whereas DNA
extracted from blood comes largely from a mixture of white blood cells. One specific
feature of B-cells is that each B-cell has been subject to its own pattern of rearrangements
around the immunoglobulin genes via the process of V-D-J recombination 28. This
suggests a natural candidate for our observed DNA source effect, and indeed the CNV
illustrated in Box Figure 2 is located close to one of the immunoglobulin genes, as are the
other instances we have found of similar gross DNA source effects. But it is not the
whole story. Principal components analysis of genome-wide intensity data with any
probe mapping to within 1Mb of an immunoglobulin gene excluded from analysis
(Supplementary Figure 29) shows reasonably clear discrimination by DNA source
(though less clear than when all probes are included), with many probes, genome-wide,
contributing to the discrimination.
Dispersed duplications and DNA source effects represent somewhat interesting
biological artefacts. We also observed more prosaic effects. As one example,
Supplementary Figure 30 shows that there are systematic effects on probe intensity of the
row of the plate in which a sample was run.
Methods
Pilot Experiment
Full details are given in the SoM, but in brief a total of 384 samples from four different
collections spanning the range of DNA quality encountered in our previous WTCCC SNP-
based association study 14 were assayed for 156 previously-identified CNVs on each of
three different platforms: Agilent Comparative Genomic Hybridization (CGH), and
NimbleGen CGH (run in service laboratories) and Illumina iSelect (run at the Sanger
Institute). The pilot experiment contained many more probes per CNV (40-90 depending on
platform) than we anticipated using in the main study, and replicates of these probes, to
allow an assessment of data quality as a function of the number of probes per CNV and of
the merits of replicating probes predicted in advance to perform well, compared to using
distinct probes.
The Agilent CGH platform performed best in our pilot and we settled on an array which
comprised 105,072 long oligonucleotide probes. Based on the pilot data we aimed to target
each CNV with 10 distinct probes. Actual numbers of probes per CNV on the array varied
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from this for several reasons (see SoM and Supplementary Figure 9), and we included in our
analyses any CNV with at least one probe on the array.
Array Content, Assay, and Samples for the Main Experiment
Array Content—The GSV discovery experiment 12 involved 20 HapMap Utah residents
with European ancestry (CEU) and 20 HapMap Yoruban (YRI) individuals, and 1
Polymorphism Discovery Resource individual, assayed via 20 NimbleGen arrays containing
a total of 42,000,000 probes tiled across the assayable portion of the human reference
genome. We prioritised CNVs for our experiment based on their frequency in the discovery
sample, with those identified in CEU individuals given precedence. A total of 10,835 out of
11,700 CNVs were included from the list provided by the GSV, with those not included on
the array being present in discovery in only 1 YRI individual and not overlapping genes or
highly conserved elements. This list was augmented by any common CNVs not present
among the GSV list found from analyses of Affymetrix SNP 6.0 data in HapMap 2 samples
(83 CNVs), Illumina 1M data in HapMap 3 samples (82 CNVs), analyses of Affymetrix
500K samples (18 CNVs) 7,29,30, and from our own analyses of WTCCC1 SNP data (231
CNVs). In addition, we sought to identify copy number variants not present in the human
reference sequence through analyses of published 31,32 novel sequence insertions (292
CNVs in total). Thus in total, our array targeted 11,541 putative CNVs. Ten non-
polymorphic regions of the X-chromosome were also assayed for control purposes.
Most loci targeted on the CNV-typing array derive from microarray-based CNV discovery,
which is inherently imprecise. In contrast to SNP discovery by sequencing, arrays do not
provide nucleotide level resolution, nor do they locate additional copies of a sequence in the
genome. As a result, when CNVs called in different individuals overlap, but are not
identical, these could be called as one or two different CNVs, and where discovered CNVs
involve probes which map to multiple places in the reference genome, they might be called
as CNVs in each of these locations. Interpretation of counts of CNVs from discovery
experiments is thus not straightforward. Data on CNVs across thousands of individuals
provides added power to refine CNV definitions and derive a non-redundant set of CNVs. In
addition, our CNV-typing array draws together CNVs from different sources and additional
redundancy between these, while minimised during array design, can be identified and
removed. Analyses of the final array design revealed 434 of the 11,541 CNVs to be
redundant because they were targeted by exactly the same probes as other CNVs on the
array, and analysis of our array data revealed a further 213 of 562 CNVs to be redundant
from instances where overlapping CNVs passing QC were called as distinct in discovery yet
had effectively identical copy-number calls. See SoM section 3.1 for further details on array
content.
Assay—Arrays were run at Oxford Gene Technology (OGT), with each plate containing
one control sample for QC purposes. Primary data and low-level summary statistics were
produced at OGT. All substantive data analyses were undertaken within the consortium.
Plates which failed pre-specified QC metrics were rerun on the array, and in addition we
repeated 1709 of the least well-performing samples, chosen according to our own QC
analyses. See SoM for further details.
Samples—The WTCCC CNV study analysed cases from 8 common diseases (Breast
Cancer (BC), Bipolar Disorder (BD), Coronary Artery Disease (CAD), Crohn's Disease
(CD), Hypertension (HT), Rheumatoid Arthritis (RA), Type I Diabetes (T1D), and Type 2
Diabetes (T2D)) and two control cohorts (1958 Birth Cohort (58C) and the UK Blood
Service collection (UKBS)). The number of subjects from each cohort that were analysed
and the numbers that passed each phase of the quality control (QC) procedures within this
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study are shown in Supplementary Table 7. For BD, CAD, CD, HT, RA, T1D, T2D, and the
two control cohorts, a large proportion of the subjects studied in this experiment were the
same as those in the WTCCC1 SNP genome-wide association study (GWAS)
(Supplementary Table 2). Where sufficient DNA was not available for the original
WTCCC1 individuals, additional new samples from the same cohorts were used, selected
using the same approaches used for the WTCCC1 samples. Any samples that failed any of
the relevant QC metrics in WTCCC1 were excluded from consideration for this experiment.
The BC cohort was not included in the WTCCC1 SNP GWAS study.
Data Pre-Processing, CNV Calling and Quality Control
Data Pre-Processing—For each of the targeted loci, the subset of probes that target the
locus of interest (at least 1bp overlap) whilst also targeting the least number of additional
CNVs was selected for assaying (see SoM section 4.2 for more details). A total of 16
different analysis “pipelines” were used to create one-dimensional intensity summaries for
each CNV. First, a range of different methods were used to create single intensity
measurements for each probe from the red channel (test DNA) and green channel (reference
DNA) intensity data. This included different methods for normalization of the signals (see
SoM section 4.3 for details). Secondly, some pipelines incorporated a new method called
probe variance scaling (PVS) which weights probes based on information derived from
duplicate samples (see SoM section 4.5 for details). Thirdly, some pipelines used the first
principal component of the normalized probe intensities to summarise the probe-level data
to CNV-level data, whereas other pipelines used the mean of the probe intensities. Finally,
some pipelines additionally used a linear discriminant function (LDF) to further refine the
summaries based on information from an initial round of genotype calling (see SoM section
4.4 for details).
CNV Calling—Algorithmic details of the two calling methods used (“CNVtools” and
“CNVCALL”) are provided in SoM section 6. Each method was applied separately to the
intensity summaries created from each of the 16 pre-processing pipelines for each CNV
locus.
Quality Control—Samples were excluded on the basis of sample handling errors, evidence
of non-European ancestry, evidence of sample mixing, manufacturer's recommendations on
data quality, outlying values of various pre-calling and post-calling quality metrics, and
identity or close relatedness to other samples (see SoM section 5.1 for further details). To
choose which pipeline to use for a given CNV we used the pipeline which gave the highest
number of classes, and the highest average posterior probability in cases where more than 1
pipeline gave the same maximum number of classes. CNVs were excluded that had identical
probe sets to other CNVs, that were called with 1 class in all pre-processing pipelines, that
had low average posterior calls in all pre-processing pipelines, or that had a high calls
correlation with an overlapping CNV (see SoM section 5.2 for further details).
Properties of CNVs
Single class CNVs—Supplementary Table 15 shows the proportion of the single-class
CNVs from the GSV discovery project broken down according to the number of individuals
and population(s) in which they were discovered. Of the GSV CNVs discovered in CEU,
52% are single class in our data, whereas a higher proportion (74%) of GSV CNVs
discovered exclusively in YRI are single class, as would be expected. CNVs at which
distinct copy number classes cannot be distinguished might result because: (i) although
polymorphic, the signal to noise ratio at that CNV does not allow reliable identification of
distinct copy-number classes; (ii) the copy-number variant has an extremely low population
frequency; or (iii) the CNV was a false positive in a discovery experiment and is in fact
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monomorphic. In a genuinely polymorphic CNV, the intensity measurements within a pair
of duplicates should be more similar than between a random pair of distinct individuals.
Intensity comparisons between duplicates and random pairs of individuals thus allow
estimates of the proportion of single-class CNVs which are not copy-number variable in our
data (see SoM). These estimates range from ~23% for single-class CNVs discovered in two
or more CEU individuals, to ~50% of single-class CNVs discovered exclusively in YRI (see
SoM for details). We estimate 18% of GSV CNVs discovered in CEU do not exhibit
polymorphism in our UK sample. This figure is similar to the GSV estimate for false
positives in discovery of 15% 12. Overall, considering CNVs on the array from all sources,
we estimate that 26% do not exhibit polymorphism, so that just under half of the CNVs
which appear in our data to have a single class are likely not to be polymorphic. Not all of
these will be false positives in discovery, some represent CNVs which are either unique to
the individual in which they were discovered or are extremely rare in the UK population.
Multi-class CNVs—Conrad et al 12 have estimated that 83% of the bi-allelic CNVs they
genotyped represent deletions, with the remainder being duplications. Supplementary Table
7 compares the number of copy-number classes estimated by the two calling algorithms used
in the analyses for each of the CNVs passing QC. Most differences in numbers of called
classes between the algorithms arise from CNVs where one class is very rare, and is handled
differently by the algorithms (for example called as a separate class in one algorithm but
classed as outlier samples or merged with a larger class by the other).
These 3,432 CNVs include 80% of the CNVs genotyped on the Affymetrix 6.0 array that are
common (MAF > 5%) in a population with European ancestry 33, conversely only 15% of
the common CNVs we called could be called using the Affymetrix 6.0 array.
Allele Frequencies—We calculated minor allele frequencies (MAFs) for 2- and 3-class
CNVs by assuming these CNVs were biallelic and using the expected posterior genotype
counts (see SoM section 7.3 for further details).
Tagging by SNPs—In order to determine how well-tagged the CNVs analysed in our
experiment were by SNPs, we carried out correlation analyses using control samples that
were common to the current studies and other WTCCC studies. We analysed three different
collections of SNPs. We used imputed HapMap2 SNP calls in the WTCCC1 study which
used the Affymetrix 500k array, and actual calls from the WTCCC2 study using both the
Affymetrix 6.0 array and a custom Illumina 1.2M array. In all cases we used samples from
the UKBS collection (see SoM section 7.1 for further details).
Geographical Variation—Geographical information, at the level of 13 pre-defined
regions of the UK, was available for 82% of the samples in our study and we undertook
analyses for differences in copy-number class frequencies between regions. The results,
shown in Supplementary Figure 24 confirm that there is no major genome-wide population
structure, but that, unsurprisingly, there is differentiation at CNVs within HLA. It does not
seem easy to determine whether other regions with low p-values in this test represent
genuine departures from the null hypothesis of no differentiation, rather than chance effects,
though we note that the third most regionally differentiated CNV outside the HLA
(CNVR7722.1, p = 3 × 10−5, 12-df) is a deletion located within the gene LILRA3, which
may act as soluble receptor for class I MHC antigens, and so would be consistent with the
observed HLA stratification. This deletion is also the subject of a reported disease
association 34 in multiple sclerosis, a finding which may require some caution given the
level of geographical stratification at this CNV in our data. See SoM section 9.1 for further
details.
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Association Testing
Diagnostic plots such as quantile-quantile (QQ) and cluster plots were created using R.
Cluster plots were visually inspected for all CNVs with putative associations.
Principal component analysis (PCA) was applied to the summarised intensity levels for all
CNVs, and for all samples which passed QC. Plots of the first ten principal components
were coloured by various sample parameters and these revealed some of the artefacts
described in the box.
Where possible, replication was carried out by using data from other studies for SNPs that
tag the CNVs of interest. Where there was no SNP tag available, breakpoint or direct
quantitative CNV assays were designed (see SoM section 9 for further details).
We used a two-sided Wilcoxon signed-rank test to test for differences between distributions
of Bayes factors between different subsets of CNVs (those which delete all or part of an
exon vs. those which do not, and CNVs that are well-tagged by SNPs vs. those which are
not well-tagged). Further details are given in SoM section 9.5)
Testing for population stratification—All our samples are from within the UK, and we
have excluded any for which the genetic data suggests evidence of non-European ancestry.
All collections in this study, apart from breast cancer, were involved in the WTCCC SNP
GWAS, and across these collections, 80% of samples coincided between the two studies.
Analysis of the WTCCC SNP data 14 established that population structure was not a major
factor confounding association testing. Similar analyses using SNP data available for the
breast cancer samples yielded similar results (data not shown). These SNP results reinforce
the evidence from the QQ-plots in Supplementary Figure 23 and our geographical analyses
of the CNV data.
Expanded reference group analysis—In addition to our primary case-control
analyses, following 14 we also undertook expanded reference group analyses, in which copy-
number class frequencies in cases for a particular disease are compared with those for
controls and the other diseases with no aetiological or known genetic connection (see
Supplementary Table 10 for details).
Other Analyses
We used information on variability between duplicate samples to determine whether CNVs
called with 1 class show signals of polymorphism (details are given in SoM section 9.2).
We used estimates of the number of common autosomal CNVs segregating in a population
of European ancestry from Conrad et al. to estimate the coverage of common autosomal
CNVs in our study (see SoM section 9.3 for further details).
We designed a series of PCR primers to further analyse the complex signals associated with
CNVR5583.1 found in the TSPAN8 region. Further details are given in SoM section 9.4.
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Box Figure 1.
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Box Figure 2.
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Box Figure 3.
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Figure 1. Flow-chart showing which CNVs are included on the array
The chart shows the reasons for CNVs being removed from consideration (the column of
arrows and text to the right of the figure) from those originally targeted on the array and the
number of CNVs remaining at each stage of filtering.
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Figure 2. Illustrative CNVs
Histograms of three multiallelic CNVs (one per row) previously reported to be associated
with autoimmune diseases: Beta-Defensin (CNVR3771.10), CCL3L1 (CNVR7077.12) and
FCGR3B (CNVR383.1), showing 6, 5, and 4 fitted copy number classes respectively.
The histogram of normalised intensity ratios is shown for one control and the three
autoimmune collections. Histograms are overlaid by the fitted distribution used to model
each class (variously the red, blue, light green, cyan, magenta and dark green curves). In all
such figures, the area under the fitted curve of a particular colour is the same for all
collections at the same CNV.
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Figure 3. Genome-wide association results
Distribution of −log10(p) along the 23 chromosomes where p is the p-value for the one
degree-of-freedom test of association for each disease. The x-axis shows the chromosomes
numbered from 1 (on the left) to X (on the right). CNVs included in these plots were filtered
on the basis of a clustering quality score (see SoM for details) and manual inspection of the
most significant associations. The two apparent associations on chromosome 2 for
rheumatoid arthritis and type 1 diabetes result from a dispersed duplication in which the
variation is actually located within the HLA locus (see Box).
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Table 1
Summary of the discovery source for genomic regions targeted on the WTCCC CNV
genotyping array
GSV CNVs were prioritised according to extent of polymorphism in European discovery samples. See Online
Methods for full details of other sources.
Source of Loci
Number of
loci
targeted
Number of
loci
analysed
Number of
loci
polymorphic
with good
calls
CNVs GSV Discovery Project 10,835 10,217 3,096
Affymetrix 500k 18 14 12
Affymetrix 6.0 83 81 47
Illumina 1M 82 81 18
WTCCC CNV Loci 231 209 108
Novel Sequence Novel Insert Regions 292 292 151
Total 11,541 10,894 3,432
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